Kailera Therapeutics is plotting an IPO to raise additional capital for its obesity portfolio, following one of biotech’s biggest fundraisings in 2025. The report frames the move as a way to push its obesity pipeline further through the clinic in a market dominated by next-generation obesity contenders. A separate item in the list says Kailera plans an IPO for a Phase 3 obesity drug from Hengrui, positioning the company for execution risk typical of late-stage obesity programs—manufacturing scale, pivotal endpoints, and competitive differentiation. Together, the IPO planning highlights how obesity remains a capital-intensive arena where companies are choosing public markets to extend runway and de-risk pivotal trials amid heavy competition from large incumbents and well-funded peers.